Skip to main content
The American Journal of Case Reports logoLink to The American Journal of Case Reports
. 2025 Apr 25;26:e946691. doi: 10.12659/AJCR.946691

Capnocytophaga canimorsus from Dog Saliva Exposure Causing Severe Sepsis in a Healthy Adult: A Case Report

Megan A Stephens 1,D,E,F, Nawras Silin 2,A,B,D,E,, Tahani Dakkak 1,A,D,E,F, Sangamithra Sathian 2,F, Aditya K Ghosh 3,B,E, Hardeep Singh 1,A,C,D,E,F, Navneeth Bongu 4,E,4
PMCID: PMC12035970  PMID: 40279321

Abstract

Patient: Male, 63-year-old

Final Diagnosis: Capnocytophaga canimorsus infection

Symptoms: Weakness • confusion • neck pain • joint pain • low back pain • pain in the proximal thighs

Clinical Procedure: —

Specialty: Infectious Diseases • General and Internal Medicine

Objective:

Unusual clinical course

Background:

Capnocytophaga canimorsus is a gram-negative bacterium commonly found in the saliva of dogs and cats. It has the ability to evade the human immune system and cause life-threatening infections, particularly in immunocompromised individuals. C. canimorsus infection was first described in 1976, and additional cases have since been reported, with complications varying from mild to severe. This case report highlights the occurrence of a severe C. canimorsus infection in an immunocompetent patient, which rapidly progressed to septic shock and multiorgan failure.

Case Report:

We present the case of a 63-year-old man with no significant past medical history who presented with weakness, fatigue, and confusion. Further investigation revealed a wound on his lower right extremity, which had been licked by his dog. The causative pathogen was identified as C. canimorsus through blood culture and mass spectrometry. The patient experienced septic shock with multiorgan failure, including acute renal failure, liver failure, and coagulopathy. Prompt initiation of empirical broad-spectrum antibiotics prior to identification of the source of infection proved to be beneficial, resulting in clinical and symptomatic improvement for the patient.

Conclusions:

This case emphasizes the severe complications that can arise from C. canimorsus infection in immunocompetent individuals, underscoring the importance of early recognition and treatment in cases of sepsis, particularly in those with potential dog saliva exposure.

Key words: Capnocytophaga, Saliva, Sepsis

Introduction

Capnocytophaga canimorsus is a gram-negative bacterium found in the oral cavity of up to 74% of dogs and 57% of cats [1]. While it is a commensal bacterium that is part of the normal oral flora of these animals, in rare cases, it can cause illness in humans. The annual human infection rate is approximately 0.5 to 0.7 cases per million individuals [2]. C. canimorsus is transmitted to humans through bites, scratches, licks, or close contact with infected animals. The bacterium can also be transmitted when an animal’s saliva comes into contact with open wounds or mucus membranes [3]. The infection rate of C. canimorsus from dog bites is reported to be 3% to 18% [4]. Common clinical manifestations of C. canimorsus infection include localized wound infections, characterized by blistering, erythema, swelling, purulent drainage, or pain at the wound site. Systemic symptoms can include fever, chills, diaphoresis, generalized myalgia, and arthralgia. Gastrointestinal symptoms, such as abdominal pain, nausea, vomiting, and diarrhea, can also occur, along with neurological signs, including headache, confusion, and altered mentation [3].

In some cases, C. canimorsus infections in humans can rapidly progress to sepsis, due to its ability to evade the immune system’s initial defense mechanisms [5,6]. Studies have shown that macrophages infected with a strain of C. canimorsus isolated from a septicemic patient do not promote the release of proinflammatory cytokines [7]. Furthermore, C. canimorsus has been found to be enveloped by a polysaccharide capsule, contributing to increased resistance for phagocytosis [5,8,9]. Diagnosis is typically confirmed via blood culture, although the organism’s slow growth can make identification through automated blood culture systems challenging. More reliable diagnostic methods include polymerase chain reaction (PCR), 16S ribosomal ribonucleic acid (rRNA) gene amplification, and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) [10].

Infections caused by C. canimorsus are more commonly seen in individuals with immunodeficiency, including those with hematologic malignancies, asplenia, and cirrhosis [11,12]. Complications can range from mild to severe, including localized cellulitis, sepsis, meningitis, thrombocytopenic purpura, disseminated intravascular coagulation (DIC), acute endocarditis, and gangrene [3,12,13]. Furthermore, multiorgan failure can occur due to septic shock with acute renal failure and/or respiratory failure [13]. Treatment options include parenteral antibiotic treatment and oral antibiotic treatment, generally for 2 to 3 weeks [14]. Despite these interventions, the fatality rate remains high, occurring in 24% to 30% of cases [15].

Previous reports have documented septic shock and multi-system organ failure in immunocompromised patients following C. canimorsus infection. Risk factors for bacteremia due to C. canimorsus include a history of splenectomy, excessive alcohol use, cirrhosis, cancer, chronic lung disease, immunodeficiency, and diabetes [1012]. However, such occurrences are rare in otherwise healthy patients. Here, we present the case of an initial presentation of weakness, joint pain, myalgia, and altered mentation in the setting of C. canimorsus septicemia, complicated by DIC, acute renal failure, and shock liver. Despite the rarity of C. canimorsus in immunocompetent individuals, this case report highlights the importance of recognizing C. canimorsus in patients with potential exposure to dog saliva and subsequent sepsis.

Case Report

A 63-year-old man with no significant medical history presented to the Emergency Department with symptoms of weakness, confusion, neck pain, joint pain, low back pain, and pain in the proximal thighs. He was accompanied by his wife, and they reported that symptoms had started 2 days prior. Despite a prior visit to the Emergency Department and discharge with medications for muscular spasm, his condition worsened significantly within the following 12 h. Notably, his weakness progressed to the point where he was unable to lift his legs, walk, or stand without assistance. During this time, he denied experiencing increased weakness in his upper extremities. Furthermore, he denied fever, headaches, visual changes, chest pain, shortness of breath, gastrointestinal symptoms, urinary symptoms, and sensory changes.

Upon evaluation, his vital signs revealed a respiratory rate of 30 breaths per min and blood pressure of 100/45 mm Hg. He had no fever, and his oxygen concentration was normal. Electrocardiography revealed normal sinus rhythm, with a rate of 87 beats per min, and no acute ischemic changes. Laboratory findings revealed significant abnormalities, including elevated levels of blood urea nitrogen at 52 mg/dL and serum creatinine at 4.42 mg/dL, indicating impaired renal function. Liver function tests revealed significantly elevated levels of aspartate transaminase >6000 U/L and alanine transaminase at 3928 U/L, consistent with liver damage. Additional findings included white blood cell count of 8.4 K/μL, with 55% bands, lactate level of 5.5 mmol/L, and platelet count of 31 K/μL, confirming the diagnosis of severe sepsis. Additionally, the DIC profile revealed a prothrombin time of 21.9 s, D-dimer greater than 4000 μg/mL, and fibrinogen of 99 mg/dL (Table 1).

Table 1.

Significant laboratory findings on admission.

Parameter Value Unit Reference range
BUN 52 mg/dL 6–20 mg/dL
Creatinine 4.42 mg/dL 0.6–1.3 mg/dL
AST >6000 U/L 8–33 U/L
ALT 3928 U/L 4–36 U/L
WBC 8.4 K/μL 4–10.8 K/μL
Bands (%) 55 % 3 to 5%
Platelet 31 K/μL 150–450 K/μL
Troponin 113 ng/L <14 ng/L
CRP 24.7 mg/L <10 mg/L
CK total 590 U/L 40–320 U/L
HCO3 13.8 mmol/L 23–27 mmol/L
Lactate 5.5 mmol/L <2 mmol/L
PT 21.9 seconds 9.4–12.5 seconds
Fibrinogen 99 mg/dL 196–493 mg/dL
D-Dimer >4000 μg/mL (FEU) ≤0.400 μg/mL (FEU)

BUN – blood urea nitrogen; AST – aspartate transaminase; ALT – alanine transaminase; WBC – white blood cell count; CRP – C-reactive protein; CK – creatine kinase; HCO3 – bicarbonate; PT – prothrombin time; FEU – fibrinogen equivalent units.

Imaging studies revealed left lower lobe pneumonia, persistent bilateral nephrograms, concerning for acute tubular necrosis without hydronephrosis or perinephric fluid collection, and mild hepatomegaly (Figure 1). Neurology consultation led to a diagnosis of inflammatory and immune myopathies, for which the patient was initiated on intravenous immunoglobulin and methylprednisolone, leading to symptomatic improvement. Additional imaging, including magnetic resonance imaging of the brain and spine and a pan computed tomography scan, was recommended to rule out malignancy.

Figure 1.

Figure 1.

Contrasted computed tomography of the chest, abdomen, and pelvis, which revealed mild bilateral atelectasis, persistent bilateral nephrograms concerning for acute tubular necrosis without hydronephrosis or perinephric fluid collection (green arrows), and mild hepatomegaly (red arrow).

The patient was admitted to the Intensive Care Unit (ICU) for the treatment of septic shock, thrombocytopenia, renal dysfunction, and liver failure. He received aggressive resuscitation with intravenous fluids and vasopressors. Broad-spectrum antibiotics were also initiated empirically for septic shock. The antibiotic course included ampicillin and acyclovir on day 1, vancomycin day 2 to day 4, meropenem day 2 to day 8, doxycycline day 2 to day 8, and micafungin day 3 to day 7.

Additionally, an autoimmune workup, including tests for anti-nuclear antibody, anti-smooth muscle antibody, and ganglioside antibodies (GQ1b IgG and IgM, GD1b IgG and IgM), was done and yielded negative results. C-reactive protein level was elevated at 22.5 mg/dL, and ADAMTS13 activity was reduced to 30%. However, blood cultures returned positive for gram-negative rods (Figure 2), later identified as C. canimorsus, using MALDI-TOF, which identifies slow-growing bacteria. A wound on his right shin, which had been licked by his dog was identified as the source of infection (Figure 3). Notably, we were unaware whether the patient’s dog was tested for the presence of C. canimorsus in the saliva.

Figure 2.

Figure 2.

Capnocytophaga canimorsus Gram stain image, showing gram-negative fusiform bacilli. Sample culture image obtained from the Microbiology Department at Northeast Georgia Medical Center.

Figure 3.

Figure 3.

Infected wound on the patient’s right shin, characterized by necrosis. The wound features a central black eschar, surrounded by a violaceous (purple) and erythematous (red) rim. The estimated size of the necrotic center is 0.5 to 1 cm, with surrounding erythema and induration extending 1 to 2 cm beyond it.

The broad-spectrum antibiotic regimen for septic shock, although nonspecific, effectively covered the bacterial infection and was discontinued on day 8. The Infectious Disease Department was consulted and subsequently started the patient on intravenous ampicillin/sulbactam on day 9, continuing until day 15, one day before discharge. The targeted antibiotic for C. canimorsus is ampicillin/sulbactam; however, considering that meropenem is broad-spectrum, the total duration of antibiotic therapy was 2 weeks. Leukocytosis peaked on day 2 at 35.2 K/μL but steadily improved over the hospital course to within the reference range prior to discharge. The Infectious Disease Department continued to monitor his progress, with repeat blood cultures yielding negative results.

Nephrology consultation was sought due to acute kidney injury, which necessitated continuous renal replacement therapy, and the patient was later transitioned to hemodialysis.

The Nephrology Department continued to monitor the patient throughout the hospital course. Additionally, the patient received a diagnosis of DIC and shock liver, for which he received platelet transfusions, N-acetylcysteine infusion, and cryoprecipitate, resulting in clinical and laboratory improvement. Thrombocytopenia improved, with full resolution prior to discharge.

The patient demonstrated significant clinical improvement throughout the hospital course. His blood pressure readings stabilized to the 120s to 150s systolic and 70s to 90s diastolic. Confusion resolved on day 5. Fatigue and weakness improved throughout the hospital course, and he was able to ambulate on day 11. Physical therapy interventions resulted in significant functional improvement, as evidenced by an Activity Measure for Post-Acute Care score of 23 of 24.

He underwent vascular surgery consultation for the exchange of his temporary hemodialysis catheter to a tunneled catheter. Upon discharge on day 16, the patient continued outpatient hemodialysis 3 times per week. He was advised to follow up with nephrology and primary care physicians within 1 to 2 weeks. Approximately 1 month after discharge, the patient continued to require hemodialysis 3 times per week. He still reported residual generalized weakness and fatigue, although significantly improved from before.

Discussion

From this case report, we learn that C. canimorsus infection, although rare, can cause severe and life-threatening complications, even in immunocompetent individuals. This highlights the importance of considering C. canimorsus in the differential diagnosis of sepsis, particularly in patients with a history of exposure to dog saliva, as prompt recognition and treatment are crucial for favorable outcomes. This is a rare case of gram-negative sepsis due to C. canimorsus, which was complicated by multisystem organ failure, including acute renal failure/acute tubular necrosis, liver failure, and DIC. Septic shock has been reported in only 13% of C. canimorsus cases [16]. In a previous retrospective study involving patients with C. canimorsus bacteremia who were admitted to an ICU, organ dysfunction was commonly observed, with coagulopathy affecting 94% of cases, and acute kidney injury occurring in 69% of patients [17]. Renal replacement therapy emerged as the primary treatment modality for acute kidney injury in this context [18]. Notably, a similar prior case of septic shock with acute liver failure, acute tubular necrosis requiring renal replacement therapy, and DIC occurred in a 38-year-old male patient; however, the patient did have a history notable for excessive alcohol use [19]. In the case of our patient, he did not possess any known lifestyle risk factors.

Furthermore, individuals with splenectomies comprise 60% of C. canimorsus infections [10]. Notably, our patient did not have a history of asplenia, immunodeficiency, or cirrhosis. In addition, while immunocompromised patients are known to be at higher risk for C. canimorsus complications, it is noteworthy that up to 40% of infection cases occur in individuals without underlying immunocompromised states, such as in the case of our patient [15,20]. In a previous observational study and systemic review of all cases of C. canimorsus, a total of 128 cases were identified in immunocompetent patients from 2002 to 2019. This study concluded that C. canimorsus infection is frequently complicated by sepsis in immunocompetent individuals; 74.2% of cases were male patients [21]. Furthermore, male patients over the age of 50 (median age of 58) years seem to be at greater risk than the general population [16,21]. As a man in his 60s, our patient did possess these risk factors. On the other hand, it was found that a fatal outcome can be prevented, despite risk factors, by early wound cleansing, initial antibiotic treatment with penicillin beta-lactamase inhibitor combinations, and surgical excision of the infection site [21].

The typical incubation period of C. canimorsus is approximately 1 to 8 days [11]. Diagnosis primarily relies on blood culture, although it can be challenging to detect. Due to its fastidious culture media and slow growth in culture media, which takes 2 to 7 days on average, it can require up to 14 days to turn positive [16,22]. Early recognition is important for prompt initiation of antibiotic therapy. The recommended duration of antibiotic therapy is approximately 14 to 21 days [14]. First-line treatment for C. capnocytophaga bacteremia in immunocompetent patients includes parenteral broad-spectrum antibiotics, including beta-lactams, beta-lactam/beta-lactamase inhibitors, and/or imipenem/cilastatin [23]. As many strains of C. canimorsus are susceptible to all antibiotics, treatment with broad-spectrum antibiotics has been successful in most cases [24]. Our patient had initial treatment with empiric broad-spectrum antibiotics, which included 7 days of carbapenem. Subsequently, targeted antibiotic therapy (ampicillin/sulbactam) was administered for 7 days, totaling 2 weeks of antibiotic therapy. He demonstrated significant functional improvement on this antibiotic regimen. Notably, septic shock due to C. canimorsus does not seem to require treatments that are not included in current septic shock guidelines [18].

This case report highlights the complexities involved in diagnosing C. canimorsus infections and emphasizes the importance of early recognition. It reveals the severe and potentially life-threatening nature of C. canimorsus infection, even in otherwise healthy individuals. Moreover, this case exemplifies how C. canimorsus can progress rapidly into septic shock with multiorgan failure, which can be irreversible. As in the case of our patient, appropriate treatment of septic shock can prevent further detriment of C. canimorsus septicemia.

Conclusions

Our patient presented with systemic symptoms and was later found to have septic shock with end-stage organ failure due to C. canimorsus. This is a rare response in immunocompetent patients. Prompt initiation of empirical broad-spectrum antibiotics prior to identification of the source of infection proved to be beneficial, resulting in clinical and symptomatic improvement. In septic patients with potential dog exposure, C. canimorsus should be considered as a potential causative pathogen.

Footnotes

Publisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher

Consent Declaration

We obtained verbal consent from the patient, which was witnessed by another resident physician. The physical consent form is securely stored at the Graduate Medical Education office at Northeast Georgia Medical Center.

Declaration of Figures’ Authenticity

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part.

References:

  • 1.Suzuki M, Kimura M, Imaoka K, Yamada A. Prevalence of Capnocytophaga canimorsus and Capnocytophaga cynodegmi in dogs and cats determined by using a newly established species-specific PCR. Vet Microbiol. 2010;144(1–2):172–76. doi: 10.1016/j.vetmic.2010.01.001. [DOI] [PubMed] [Google Scholar]
  • 2.Mantovani E, Busani S, Biagioni E, et al. Purpura fulminans and septic shock due to Capnocytophaga canimorsus after dog bite: A case report and review of the literature. Case Rep Crit Care. 2018;2018:7090268. doi: 10.1155/2018/7090268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Centers for Disease Control About capnocytophaga. Capnocytophaga. May 9, 2024. Accessed June 6, 2024. Available from: https://www.cdc.gov/capnocytophaga/about/index.html.
  • 4.Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999;340(2):85–92. doi: 10.1056/NEJM199901143400202. [DOI] [PubMed] [Google Scholar]
  • 5.Shin H, Mally M, Meyer S, et al. Resistance of Capnocytophaga canimorsus to killing by human complement and polymorphonuclear leukocytes. Infect Immun. 2009;77(6):2262–71. doi: 10.1128/IAI.01324-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mally M, Shin H, Paroz C, Landmann R, Cornelis GR. Capnocytophaga canimorsus: A human pathogen feeding at the surface of epithelial cells and phagocytes. PLoS Pathog. 2008;4(9):e1000164. doi: 10.1371/journal.ppat.1000164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shin H, Mally M, Kuhn M, et al. Escape from immune surveillance by Capnocytophaga canimorsus. J Infect Dis. 2007;195(3):375–86. doi: 10.1086/510243. [DOI] [PubMed] [Google Scholar]
  • 8.Hess E, Renzi F, Koudad D, et al. Identification of virulent Capnocytophaga canimorsus isolates by capsular typing. J Clin Microbiol. 2017;55(6):1902–14. doi: 10.1128/JCM.00249-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Renzi F, Ittig SJ, Sadovskaya I, et al. Evidence for a LOS and a capsular polysaccharide in Capnocytophaga canimorsus. Sci Rep. 2016;6(1):38914. doi: 10.1038/srep38914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Centers for Disease Control Clinical overview of capnocytophaga. Capnocytophaga. Jun 4, 2024. Accessed June 12, 2024. Available from: https://www.cdc.gov/capnocytophaga/hcp/clinical-overview/index.html.
  • 11.Chesdachai S, Tai DBG, Yetmar ZA, et al. The characteristics of capnocytophaga infection: 10 years of experience. Open Forum Infect Dis. 2021;8(7) doi: 10.1093/ofid/ofab175. ofab175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pers C, Gahrn-Hansen B, Frederiksen W. Capnocytophaga canimorsus septicemia in Denmark, 1982–1995: Review of 39 cases. Clin Infect Dis. 1996;23(1):71–75. doi: 10.1093/clinids/23.1.71. [DOI] [PubMed] [Google Scholar]
  • 13.Meyer EC, Alt-Epping S, Moerer O, Büttner B. Fatal septic shock due to Capnocytophaga canimorsus bacteremia masquerading as COVID-19 pneumonia – a case report. BMC Infect Dis. 2021;21(1):736. doi: 10.1186/s12879-021-06422-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Capnocytophaga spp. | Johns Hopkins ABX Guide. Accessed June 17, 2024. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540078/all/Capnocytophaga_spp_?refer=true.
  • 15.Nakayama R, Miyamoto S, Tawara T, et al. Capnocytophaga canimorsus infection led to progressively fatal septic shock in an immunocompetent patient. Acute Med Surg. 2022;9(1):e738. doi: 10.1002/ams2.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Janda JM, Graves MH, Lindquist D, Probert WS. Diagnosing Capnocytophaga canimorsus infections. Emerg Infect Dis. 2006;12(2):340–42. doi: 10.3201/eid1202.050783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hästbacka J, Hynninen M, Kolho E. Capnocytophaga canimorsus bacteremia: Clinical features and outcomes from a Helsinki ICU cohort. Acta Anaesthesiol Scand. 2016;60(10):1437–43. doi: 10.1111/aas.12752. [DOI] [PubMed] [Google Scholar]
  • 18.Sardo S, Pes C, Corona A, et al. The Great pretender: The first case of septic shock due to Capnocytophaga canimorsus in Sardinia. A Case report and review of the literature. J Public Health Res. 2022;11(4) doi: 10.1177/22799036221133234. 22799036221133234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ahsen A, Korsun P, Albahra F, et al. Capnocytophaga canimorsus infection in a 38-year-old male after a dog bite. Case Rep Infect Dis. 2023;2023:9917898. doi: 10.1155/2023/9917898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lion C, Escande F, Burdin JC. Capnocytophaga canimorsus infections in human: Review of the literature and cases report. Eur J Epidemiol. 1996;12(5):521–33. doi: 10.1007/BF00144007. [DOI] [PubMed] [Google Scholar]
  • 21.Mader N, Lührs F, Langenbeck M, Herget-Rosenthal S. Capnocytophaga canimorsus. Capnocytophaga canimorsus – a potent pathogen in immunocompetent humans – systematic review and retrospective observational study of case reports. Infect Dis (Lond) 2020;52(2):65–74. doi: 10.1080/23744235.2019.1687933. [DOI] [PubMed] [Google Scholar]
  • 22.Hansen M, Crum-Cianflone NF. Capnocytophaga canimorsus meningitis: Diagnosis using polymerase chain reaction testing and systematic review of the literature. Infect Dis Ther. 2019;8(1):119–36. doi: 10.1007/s40121-019-0233-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Jolivet-Gougeon A, Sixou JL, Tamanai-Shacoori Z, Bonnaure-Mallet M. Antimicrobial treatment of Capnocytophaga infections. Int J Antimicrob Agents. 2007;29(4):367–73. doi: 10.1016/j.ijantimicag.2006.10.005. [DOI] [PubMed] [Google Scholar]
  • 24.Sandoe JAT. Capnocytophaga canimorsus endocarditis. J Med Microbiol. 2004;53(Pt 3):245–48. doi: 10.1099/jmm.0.05274-0. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Case Reports are provided here courtesy of International Scientific Information, Inc.

RESOURCES